Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is a clinical-stage biotechnology company with a positive outlook from a financial analyst due to its potential to create innovative therapies for chronic inflammatory diseases. The company's pipeline products, EVO756 and EVO301, target key factors driving chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The analyst acknowledges the regulatory risk involved in gaining approval for these drugs, but believes that the company's risk-adjusted sum-of-the-parts valuation and emerging early pipeline provide potential for long-term upside. The recent failure of EVO756 in the Ph2b trial for atopic dermatitis is seen as a disappointment, but the focus is now on the potential for EVO301 in AD and proof-of-concept for '756 in migraine. The analyst lowers the price target to $21 but maintains an Outperform rating due to the company's differentiated approach and potential in the migraine market. The company may face sustainability issues in the future, but its differentiated approach to targeting X2 expression in other indications provides potential for success. Upcoming catalysts include detailed data for '301 in AD, Ph.II data for '756 in migraine, and the initiation of a Ph.IIb study for '301 in AD.

Bears say

Evommune is facing financing risk as it has a substantial need for additional capital prior to reaching profitability. They have had negative clinical trial results for their lead program EVO756 in AD, which is a highly competitive market. While they have a positive phase 2a trial for their lead program EVO301 in AD, it has yet to be tested in larger studies and faces competition from established biologics and emerging therapies. Additionally, EVMN's focus on progressing a drug to market rather than sustainability could be a concern for potential investors.

Evommune Inc (EVMN) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 9 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.